Evidence map›Paper›PMID 41640990›Full record

ArticleCell stress2026

Antifungal peptides: From modes of action to synergistic and immunologic potential.

Didac Carmona-Gutierrez, Maria A Bauer, Katharina Kainz, Martin N Odabas, Frank Madeo

Abstract read
In one paragraph

Article in Cell stress, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Didac Carmona-GutierrezInstitute for Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
Maria A BauerInstitute for Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
Katharina KainzInstitute for Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
Martin N OdabasInstitute for Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.
Frank MadeoInstitute for Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal infections pose a significant global health threat with rising morbidity and mortality rates. However, the repertoire of effective antifungal drugs remains narrow, a challenge that is further exacerbated by the increasing emergence of (multi)drug-resistant strains. This underscores the urgent need for novel therapeutic strategies. Among them, antifungal peptides (AFPs) have emerged as a promising alternative. AFPs are small, naturally occurring peptides produced by a wide range of organisms, including plants, animals, fungi, and bacteria, as part of their innate immune defense. In addition, synthetic and semisynthetic variants have also been engineered. We here underscore the potential of AFPs as viable candidates for the development of next-generation antifungal therapies. In particular, we advocate their multimodal advantage that spans beyond standalone activity, including their synergistic and immune-regulatory potential.

Indexed as

antimycoticsazolesCandidadrugimmune systemresistanceyeast

Identifiers

PMID41640990
PMCPMC12867486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.